A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms REALISTIC
- Sponsors UCB Pharma Inc
- 13 Jun 2024 According to UCB media release, data of this will be presented at the European Congress of Rheumatology, EULAR 2024, and provide evidence to inform personalized treatment decisions for patient populations with high unmet need
- 25 Aug 2012 Results published in the Rheumatology.
- 09 Jun 2012 Relationship between timing and magnitude of initial response and likelihood of low disease activity at week 28 results presented at the 13th Annual Congress of the European League Against Rheumatism.